Wednesday, July 29, 2015
 
 
Company News: Page (1) of 1 - 02/24/12 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Burrill & Company Expands Into Taiwan
Marietta Wu, Promoted to Managing Director, Taiwan, Will Head New Office
(February 24, 2012)

SAN FRANCISCO, CA -- (Marketwire) -- 02/24/12 -- Burrill & Company says it will open an office in Taiwan led by Marietta Wu, M.D., Ph.D., whom the company has promoted to Managing Director, Taiwan.

"Taiwan is in a strategically important region offering tremendous opportunities. By investing there, we can broaden access to emerging markets in China and East Asia. At the same time, we offer companies in Taiwan a window on innovation in the West and can help them grow their companies into players on the global stage," says G. Steven Burrill, CEO of Burrill & Company, a diversified global financial services firm focused on the life sciences industry. "We are pleased to have someone with Marietta's depth of experience lead our effort there."

Wu, who joined Burrill & Company's venture group in 2006, will open and manage the office, serve as the principal point of contact for the venture group's investors in Taiwan, and manage investments in Taiwan-based companies.

At Burrill, Dr. Wu has led investments in companies and fundraising efforts in Taiwan. She also served as acting COO of Waterstone Pharmaceuticals, a Burrill portfolio company. Prior to joining Burrill, Dr. Wu held professional positions with Edwards Lifesciences and Eli Lilly. As Director of Strategy at Edwards, Dr. Wu was responsible for strategic planning in its biologics program. At Eli Lilly Oncology and Integrated Biology, she oversaw finance, business development, pipeline valuation, organizational restructuring, and outsourcing strategy. She also worked at Eli Lilly's M&A Group and with Oncology Discovery Research. Dr. Wu founded BioHorizon, a consultancy focused on value creation in the life sciences industry across the Pacific Rim. She advised a number of biotech start-ups and venture capital firms.


Dr. Wu's scientific expertise centers on basic and clinical research in oncology and neuroscience. She was selected by Nobel Laureate Dr. Marshall Nirenberg as an IRTA Fellow at the National Institutes of Health. She received her M.D. from Shanghai Jiaotong University School of Medicine, a Ph.D. in Medical Sciences from Medical College of Ohio, and an MBA from the University of Michigan Business School.

About Burrill & Company
Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With $1.5 billion in assets under management, the firm's businesses include venture capital/private equity, merchant banking, and media. By leveraging the scientific and business networks of its team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, transactional support, management expertise, insight, market intelligence, and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe, and Asia. For more information visit: www.burrillandco.com.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Daniel Levine
Managing Director
Burrill & Company
Email Contact
415-591-5449


Copyright @ Marketwire

Page: 1


Related Keywords: Burrill & Company, USA, China, Taiwan, Marketwire, , Financial, Medical, Biology, Business, china,
Related Sites: itbusinessnet.com ,   HTN - Health Technology Net
Related Newsletter:
 
 
 
 
 
Seniors

Drugs
  • Children's Medical Safety Research Institute Announces Innovative Study on Alzheimers Treatment Is Subject of Crowd Funding Campaign
  • Soft Tissue Repair Market by Product by Application - Global Forecast to 2019
  • Pregnancy: Not Just a Nine Month Stint Anymore
  • Global 2D X-Ray Equipment Market Will Reach $16.9 Billion By 2021: Acute Market Reports
  • FDA approves Novartis drug Odomzo (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer

    Cancer
  • Scottsdale Plastic Surgeon Rozbeh Torabi MD Opens New Office, Scheduling New Patients
  • Varian Medical Systems Acquiring Claymount to Expand Imaging Components Portfolio
  • Varian Medical Systems Acquiring Claymount to Expand Imaging Components Portfolio
  • Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc
  • Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2015
  •  
     
     
     
     
     





    About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines